Clinical Effects of Doxazosin in Essential Hypertension.
10.4070/kcj.1991.21.4.745
- Author:
Young Don JOO
;
In Hee LEE
;
Dong Soo KIM
;
Kyung Soon LEE
- Publication Type:Original Article
- Keywords:
Doxazosin;
Essential hypertension
- MeSH:
Blood Pressure;
Cholesterol;
Dizziness;
Doxazosin*;
Fatigue;
Heart Rate;
Humans;
Hypertension*;
Vertigo
- From:Korean Circulation Journal
1991;21(4):745-750
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The antihypertensive efficacy and safety of doxazosin, a selective alpha1-inhibitor, were assessed in 20 patients with essential hypertension. Doxazosin induced a clinically significant reduction in blood pressure(26.0mmHg in systolic blood pressure and 21.7mmHg in diastolic blood pressure) with similar heart rates after 12 weeks therapy. The efficacy of doxazosin therapy was successful in 17 patients(89.5%) and failed in 2 patients(10.5%). The mean dose of the efficacy evaluable patients was 4.4mg/day. most of all patients completed for 12 weeks therapy except one patients who experienced side effects sych as vertigo, dizziness and fatigue. There were no clinically significant laboratory changes before and after the doxazosin therapy. The overall lipid profile indicated a decrease in total cholesterol with increases in HDL-cholesterol. This results indicated that doxazosin given once daily is and effective antihypertensive agent with the additional action of favorably affecting blood lipid level in the treatment of mild-to-moderate hypertension.
